Michael Barbella, Managing Editor11.04.23
No tricks or unexpected treats gained favor with MPO website visitors this past week. Just more of the usual traffic drivers: products, personnel, and procurement.
AMETEK proved most popular amongst cyberviewers with its $1.9 billion deal to acquire medical component and instrument provider Paragon Medical from American Securities affiliates. Paragon Medical serves various applications including orthopedics, minimally invasive surgery, robotic surgery, and drug delivery, and its portfolio includes single-use and consumable surgical instruments and implantable components.
Insulet and Cordance Medical nipped at AMETEK's heels with news of their respective products. Insulet amassed pageviews with word of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) launch in Germany. Also available in the United States and United Kingdom, Omnipod 5 is the first CE marked tubeless automated insulin delivery (also known as hybrid closed loop) system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System.
Cordance Medical, meanwhile, attracted the spotlight with FDA breakthrough device designation for its NeuroAccess device, NeuroAccess. Designed for patients ages 22 and older with known or suspected brain tumors, NeuroAccess helps non-invasively elevate cell-free DNA analytes in blood circulation. The technology uses focused ultrasound combined with microbubbles to safely and temporarily open the blood-brain barrier. The portable NeuroAccess device aims to bring SonoBiopsy broadly across community clinics and hospitals.
DexCom Inc. secured the week's top personnel news, having appointed Rimma Driscoll to its Board of Directors. Driscoll currently serves as executive vice president and head of Global Strategy, Commercial and Business Development, and Global BioDevices for Zoetis, the world’s leading animal health company.
AMETEK proved most popular amongst cyberviewers with its $1.9 billion deal to acquire medical component and instrument provider Paragon Medical from American Securities affiliates. Paragon Medical serves various applications including orthopedics, minimally invasive surgery, robotic surgery, and drug delivery, and its portfolio includes single-use and consumable surgical instruments and implantable components.
Insulet and Cordance Medical nipped at AMETEK's heels with news of their respective products. Insulet amassed pageviews with word of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) launch in Germany. Also available in the United States and United Kingdom, Omnipod 5 is the first CE marked tubeless automated insulin delivery (also known as hybrid closed loop) system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System.
Cordance Medical, meanwhile, attracted the spotlight with FDA breakthrough device designation for its NeuroAccess device, NeuroAccess. Designed for patients ages 22 and older with known or suspected brain tumors, NeuroAccess helps non-invasively elevate cell-free DNA analytes in blood circulation. The technology uses focused ultrasound combined with microbubbles to safely and temporarily open the blood-brain barrier. The portable NeuroAccess device aims to bring SonoBiopsy broadly across community clinics and hospitals.
DexCom Inc. secured the week's top personnel news, having appointed Rimma Driscoll to its Board of Directors. Driscoll currently serves as executive vice president and head of Global Strategy, Commercial and Business Development, and Global BioDevices for Zoetis, the world’s leading animal health company.